| Steven Forsey, AUD | |
|
1055 N 300 W, Ste 401, Provo, UT 84604-3344 | |
| (801) 357-7499 | |
| (801) 373-5980 |
| Full Name | Steven Forsey |
|---|---|
| Gender | Male |
| Speciality | Qualified Audiologist |
| Experience | 13 Years |
| Location | 1055 N 300 W, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053691246 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 8006991-4101 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peak Ent Associates | 4284781543 | 27 |
News Archive
Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.
Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient's blood after intake and are unable to pinpoint the targeted tumor. As a result, while killing the tumor cells, the healthy cells may also be killed as "collateral damage", leading to undesired side effects.
An international scientific team has discovered a gene associated with a high risk of severe childhood asthma. The specific gene variant may be an actual cause of this form of asthma, a leading cause of hospitalization in young children.
Scientists at Karolinska Institutet have evaluated a new Alzheimer's therapy in which the patients receive an implant that stimulates the growth of a certain type of nerve cell. The results, which are published in the scientific journal Alzheimer's & Dementia, suggest that the introduction of a nerve growth factor can prevent neuronal degradation in Alzheimer's patients.
A new study published in the journal Substance Use and Misuse has found that adverse childhood experiences, such as physical and sexual abuse and neglect, predict greater performance-enhancing substance use in young adults.
› Verified 1 days ago
| Provider Name | Peak Ent Associates |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1346489036 PECOS PAC ID: 4284781543 Enrollment ID: O20090402000646 |
News Archive
Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.
Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient's blood after intake and are unable to pinpoint the targeted tumor. As a result, while killing the tumor cells, the healthy cells may also be killed as "collateral damage", leading to undesired side effects.
An international scientific team has discovered a gene associated with a high risk of severe childhood asthma. The specific gene variant may be an actual cause of this form of asthma, a leading cause of hospitalization in young children.
Scientists at Karolinska Institutet have evaluated a new Alzheimer's therapy in which the patients receive an implant that stimulates the growth of a certain type of nerve cell. The results, which are published in the scientific journal Alzheimer's & Dementia, suggest that the introduction of a nerve growth factor can prevent neuronal degradation in Alzheimer's patients.
A new study published in the journal Substance Use and Misuse has found that adverse childhood experiences, such as physical and sexual abuse and neglect, predict greater performance-enhancing substance use in young adults.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Forsey, AUD 1055 N 300 W, Ste 401, Provo, UT 84604-3344 Ph: (801) 357-7499 | Steven Forsey, AUD 1055 N 300 W, Ste 401, Provo, UT 84604-3344 Ph: (801) 357-7499 |
News Archive
Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.
Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient's blood after intake and are unable to pinpoint the targeted tumor. As a result, while killing the tumor cells, the healthy cells may also be killed as "collateral damage", leading to undesired side effects.
An international scientific team has discovered a gene associated with a high risk of severe childhood asthma. The specific gene variant may be an actual cause of this form of asthma, a leading cause of hospitalization in young children.
Scientists at Karolinska Institutet have evaluated a new Alzheimer's therapy in which the patients receive an implant that stimulates the growth of a certain type of nerve cell. The results, which are published in the scientific journal Alzheimer's & Dementia, suggest that the introduction of a nerve growth factor can prevent neuronal degradation in Alzheimer's patients.
A new study published in the journal Substance Use and Misuse has found that adverse childhood experiences, such as physical and sexual abuse and neglect, predict greater performance-enhancing substance use in young adults.
› Verified 1 days ago
Bennett Joseph Chargo, Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1832 N 1120 W, Provo, UT 84604 Phone: 801-495-4800 | |
Mindy Ann Norris, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-7448 | |
Adam Scott Ireland, AUD CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2230 N University Pkwy Ste 9b, Provo, UT 84604 Phone: 801-375-3175 Fax: 801-375-2818 | |
Curtis G Thomas, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1055 N 300 W, Ste 401, Provo, UT 84604 Phone: 801-357-7499 Fax: 801-373-5980 | |
Kimberly A Brauer, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3303 N University Ave, Provo, UT 84604 Phone: 801-373-7438 Fax: 013-737-4868 | |
Dr. William Kelly Dick, PHD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-373-7850 Fax: 801-357-7997 |